2 PURPOSE: Improving the consistency and reproducibility of bladder cancer prognoses necessitates the development of accurate, predictive prognostic models. Current methods of determining the prognosis of bladder cancer patients relies on manual decision-making including factors with high intra-and inter-observer variability, such as tumor grade. To advance the longterm prediction of bladder cancer prognoses, we developed and tested a computational model to predict the 10-year overall survival for bladder cancer patients without considering tumor grade classification.
If validated in clinical trials, this automated approach can guide personalized management and treatment for bladder cancer patients.
Introduction
Urothelial bladder cancer is one of the most common malignancies worldwide. It was estimated that in 2018, over 81,000 new cases of bladder cancer will be diagnosed in the United States, resulting in 17,000 deaths 1 . Although incidence rate of bladder cancer has been decreasing in recent years, disease frequently recurs while the mortality rate has remained stable 1 . Thus, the development of accurate, predictive prognostic markers is needed to better personalize healthcare management and improve patient survival, as patients with poorer prognoses may benefit from more intense follow-up, treatment, and healthcare planning. 
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Automated computational approaches have demonstrated utility in providing unbiased and reliable guidance in clinical decision-making for bladder cancer patients by exploiting large datasets 7 .
Furthermore, machine learning approaches require minimal time and resources. To demonstrate the potential utility of computational models, we had the opportunity to design and test a fully automated computational machine learning approach to predict 10-year bladder cancer survival based on factors with high reproducibility and low subjectivity, while excluding more variability histologic features such as tumor grade. Such models are of potentially clinical utility, particularly, because there is currently limited information about the predictors of long-term survival in the general population.
Methods
The overview of the pipeline for data collection, model training, and evaluation is shown in with disease-specific deaths within 10 years from the initial diagnosis, and negative samples included patients with a survival of more than 10 years from the initial diagnosis. The model was trained on the training data then evaluated on the test dataset. The model's predictions were compared to histological classification through survival analysis.
Dataset
Our study utilized 1,228 previously collected histologically confirmed bladder cancer cases from 11 . The distribution of our data is similar to that of a larger population-based dataset from the Surveillance, Epidemiology, and End Results (SEER) database 12 , which suggests generalizability of our dataset.
Outcome Status
All patients who survived from phases I and II had follow-ups for at least 120 months. The survival status of patients was determined by examining the Social Security Administration Death Master File 13 . Survival time was calculated from the date of diagnosis to the date of death for patients who did not survive, or to the date when the Death Master File was queried for patients who survived.
Patients were labeled as positives and negatives based on whether or not they survived at least 120 months after the initial diagnosis. Patients in phase III of the study were classified according to their death status at the last follow-up, which was approximately 10 years (129.0±8.90 months)
for patients who survived. To avoid misclassification, we removed patients whose causes of death were unknown or not contributed by bladder cancer. As a result, of the 1,228 bladder cancer patients, 417 were removed due to non-bladder-cancer-related deaths or unknown cause of deaths.
The remaining patients in this study included 149 persons with disease-specific deaths within 10 years after initial diagnosis, labeled as positive class, and 662 persons who survived more than 10 years, labeled as negative class. To add to the generalizability of our model, we combined data from earlier phases (Phases I and II) into training data and used phase III as testing data. The ratios between the number of positives and negatives are consistent in both training and testing datasets.
The baseline characteristics of patients included in this study are shown in Table 1 .
Missing data imputation
We implemented a data imputation strategy for missing covariate data. Training data and testing data were imputed separately. Binary variables with missing values (i.e., P53 mutation, P53
intensity, PTCH LOH positivity, high-risk occupation, family history of cancer) were imputed with 0.5 (midpoint value). Body mass index (BMI) was mean imputed. Missing values for smoke pack-years were imputed with '0' for never smokers, and with the mean pack-years for others.
Predictive Model
We implemented a logistic regression model with demographic characteristics (age and sex), risk (1)
Training and hyper-parameter tuning were done through 5-fold stratified cross-validation. Hyperparameters included a confidence score threshold and an L2 regularization parameter. The confidence score threshold was selected to classify the samples into positive and negative classes.
We used the optimal threshold to maximize the harmonic mean of sensitivity and specificity using equation (2) 
Also, the L2 regularization parameter was tuned by a log-spaced grid search in the cross-validation.
Evaluation
The trained model was evaluated on our independent, held-out test dataset using standard machine learning performance metrics of the area under the ROC curve, F1 score, sensitivity, and specificity. Survival analysis was implemented with package 'survival' 17 in R version 3. Table 2) . Although the magnitude of the effect was smaller than our model predictor, the treatment effect was statistically significant with respect to the 10-year survival, while WHO/ISUP is not ( Table 2) . 
Discussion
In this study, we developed a machine learning model that predicted 10-year survival of patients with bladder cancer. The few prior studies that have used machine learning approaches to predict bladder cancer prognoses have relied on small datasets from single hospitals, which could be biased toward specific sub-populations 6 . In order to avoid such bias and improve generalizability, we built a model using a population-based dataset. Unlike previous studies, we excluded both the WHO 1973 and the WHO/ISUP classifications from the predictive features, as these classifications are often inconsistent and add little value to our model predictions. Our model also excluded treatment information because its aim is to predict reliable prognoses before patients received their first course of treatments in order to serve as a constructive guide to aid treatment planning. The
Cox regression analysis confirmed that our model's predictions were strongly associated with the patient survival, even after adjusting for treatment. As a result, our model achieved accurate performance on a held-out test dataset in predicting bladder cancer 10-year survival outcomes. Of note, we observed including the tumor grade as an independent variable in the model did not improve its performance. This result suggested the potential for our approach to create a reliable tool to support clinicians' decision-making and patient management in practice.
In making its predictions, our model prioritized factors that are critical to the bladder cancer prognosis. For example, age, muscle invasiveness of the tumors, and smoking pack-years were among the highest-ranked variables in our final model. It is widely accepted that age is the most significant risk factor for bladder cancer occurrence 18 . The elderly patients have higher probabilities of developing muscle-invasive bladder cancer, which is also a well-established risk factor for a worse prognosis 19 . Muscle-invasive bladder cancer penetrates the central muscle layer of the bladder and is more likely to metastasize to other parts of the body 1 . More aggressive forms of treatment, such as radical cystectomy, are used for muscle-invasive bladder cancer and can pose additional risks, complications, and side effects for less tolerant elderly patients 19 . Elderly patients are also subjected to the accumulation of environmental exposure to carcinogens, such as those from cigarette smoking, which is another contributing factor to the incidence of bladder cancer 1, 20 .
An important advantage of our model is its ability to handle the imbalanced survival outcomes in the dataset. The estimated 10-year survival rate of bladder cancer patients is 70%, and the patients with lower stage disease have much higher survival rates 1 . Thus, more patients have survived the 10-year mark than who have not. A common weakness of using generic machine learning models on highly imbalanced data is the tendency for a bias toward the dominant class, which can result in low sensitivity. To minimize this bias, our model adopted a class weighting technique, placing greater emphasis on correctly predicting outcomes for the minor class. Additionally, we tuned the confidence score cutoff and chose a customized classification threshold that was well-suited for our imbalanced dataset. To further address this problem, we used the harmonic mean of sensitivity and specificity, and F1 score, rather than accuracy, as the primary evaluation metrics to account for the cost of both false positives and false negatives.
A limitation of our prediction model was its relatively low sensitivity, even after the utilization of several machine learning techniques to balance the decision boundary. While low sensitivity is likely inevitable in the presence of imbalanced data, incorporating more discriminating features in a prediction model may resolve this issue. Additionally, our model includes patients' data on molecular features, such as P53 alterations, which are not routinely available for most bladder cancer patients. P53 alterations are highly prevalent among bladder tumors, and previous studies have implied the association between the mechanisms of P53 alteration and the characteristics of bladder tumors 11, 21 . Based on our results, the P53 intensity ranked highly among all predictive features, suggesting its potential value in bladder cancer prognosis. In future work, we will pursue the extraction of additional clinicopathological features to be incorporated into our prediction model. These features may not be routinely recorded in medical records; but they can be extracted from immunohistochemistry slides through automatic image analysis techniques. We expect that integrating these clinicopathological features with the presented model will improve its predictive performance. 
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